Concealed Patriot

News

GLP-1 Analogues Like Wegovy and Ozempic Not Linked to Thyroid Cancer Risk

GLP-1 Analogues Like Wegovy and Ozempic Not Linked to Thyroid Cancer

United States: The GLP-1 analogues drugs such as Wegovy, Ozempic, and others have become highly popular for limiting diabetes levels and also helping people by losing their weight.

Recently, various concerns have been raised regarding the long-term usage of drugs, which might heighten the chances of cancer related to the thyroid.

However, a Swedish study in which more than 435,000 people took part found no proof to support the idea.

Björn Pasternak, the lead study author, said, “Many people take these medicines, so it is important to study potential risks associated with them,” as US News reported.

Pasternak is the lead researcher at the department of medicine at the Karolinska Institute in Stockholm.He’s principal researcher at the department of medicine at the Karolinska Institute in Stockholm.

He added in a news release, “Our study covers a broad group of patients and provides strong support that GLP-1 analogs are not associated with an increased risk of thyroid cancer.”

More about the study

The study involved Pasternak and the whole team, which used the Knowledge gathered from a major Scandinavian database.

The information from database involving 145,000 people who were consuming GLP-1 analogues like liraglutide (Victoza) or semaglutide (Ozempic). Additionally, 290,000 people were those consuming one of another class of diabetes drugs known as DPP4 inhibitors.

The groundbreaking revelation was suggested by the study whose results were published in the journal BMJ on April 9.

Findings of the study

The study findings revealed that there are lesser chances of developing thyroid cancer in those people who were consuming GLP-1 analogs as compared to those who had DPP4 inhibitors.

Such finding repeated itself when the users of GLP-1 analogue were made to compare with those patients who were having a third class of diabetes medical treatment, which is known as SGLT2 inhibitors.

Peter Ueda, the co-author of the study and an assistant professor of medicine at the Karolinska Institute said that the final result for the GLP-1 analogues’ effect on thyroid is yet to be made certain.

Ueda added, “We cannot rule out that the risk of certain subtypes of thyroid cancer is increased in smaller patient groups that we could not study here, for example, in people with a high congenital risk of medullary thyroid cancer who are advised against using these drugs,” as US News reported.

Leave a Reply

Your email address will not be published. Required fields are marked *